EP3962497A4 - Compositions de protéines de fusion chimériques modifiées et leurs procédés d'utilisation - Google Patents
Compositions de protéines de fusion chimériques modifiées et leurs procédés d'utilisation Download PDFInfo
- Publication number
- EP3962497A4 EP3962497A4 EP20798060.8A EP20798060A EP3962497A4 EP 3962497 A4 EP3962497 A4 EP 3962497A4 EP 20798060 A EP20798060 A EP 20798060A EP 3962497 A4 EP3962497 A4 EP 3962497A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- fusion protein
- protein compositions
- chimeric fusion
- engineered chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464458—Proteinases
- A61K39/464461—Caspases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962841183P | 2019-04-30 | 2019-04-30 | |
US201962841190P | 2019-04-30 | 2019-04-30 | |
US16/827,381 US11026973B2 (en) | 2019-04-30 | 2020-03-23 | Engineered phagocytic receptor compositions and methods of use thereof |
US16/827,302 US11013764B2 (en) | 2019-04-30 | 2020-03-23 | Engineered phagocytic receptor compositions and methods of use thereof |
PCT/US2020/030837 WO2020223550A1 (fr) | 2019-04-30 | 2020-04-30 | Compositions de protéines de fusion chimériques modifiées et leurs procédés d'utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3962497A1 EP3962497A1 (fr) | 2022-03-09 |
EP3962497A4 true EP3962497A4 (fr) | 2023-01-18 |
Family
ID=73029265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20798060.8A Pending EP3962497A4 (fr) | 2019-04-30 | 2020-04-30 | Compositions de protéines de fusion chimériques modifiées et leurs procédés d'utilisation |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3962497A4 (fr) |
JP (1) | JP2022531325A (fr) |
KR (1) | KR20220045930A (fr) |
CN (1) | CN114072157A (fr) |
AU (1) | AU2020266595A1 (fr) |
BR (1) | BR112021021843A8 (fr) |
CA (1) | CA3135531A1 (fr) |
GB (1) | GB2600834A (fr) |
IL (1) | IL287650A (fr) |
MX (1) | MX2021013355A (fr) |
SG (1) | SG11202111985XA (fr) |
WO (1) | WO2020223550A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
AU2018341244A1 (en) | 2017-09-26 | 2020-03-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules and methods of use |
CA3087529A1 (fr) | 2018-01-03 | 2019-07-11 | Palleon Pharmaceuticals Inc. | Sialidases humaines recombinantes, proteines de fusion de sialidase et leurs methodes d'utilisation |
WO2021046243A2 (fr) | 2019-09-03 | 2021-03-11 | Myeloid Therapeutics, Inc. | Méthodes et compositions d'intégration génomique |
JP2023549140A (ja) | 2020-11-04 | 2023-11-22 | マイエロイド・セラピューティクス,インコーポレーテッド | 操作されたキメラ融合タンパク質組成物およびその使用方法 |
JP2024501767A (ja) * | 2021-01-06 | 2024-01-15 | パレオン ファーマシューティカルズ インコーポレイテッド | シアリダーゼ-her2-抗体融合タンパク質、及びその使用方法 |
CA3217047A1 (fr) | 2021-04-28 | 2022-11-03 | Sanquin IP B.V. | Recepteurs fc-alpha chimeriques et leurs utilisations |
CN113214408B (zh) * | 2021-04-30 | 2022-12-27 | 清华大学深圳国际研究生院 | 一种嵌合抗原受体巨噬细胞及其制备方法和用途 |
GB202108366D0 (en) * | 2021-06-11 | 2021-07-28 | Quell Therapeutics Ltd | Multichain chimeric antigen receptor |
CN113817677B (zh) * | 2021-09-29 | 2023-08-18 | 四川大学 | 泛酸或其衍生物与α-D-葡萄糖-1,6-二磷酸或其衍生物在促进DC迁移中的用途 |
WO2023194608A1 (fr) * | 2022-04-07 | 2023-10-12 | Institut Curie | Cellules myéloïdes modifiées par un récepteur antigénique chimérique et leurs utilisations pour une thérapie anticancéreuse |
WO2023194607A1 (fr) * | 2022-04-07 | 2023-10-12 | Institut Curie | Cellules myéloïdes modifiées par un récepteur antigénique chimérique avec cd40 et leurs utilisations pour une thérapie anticancéreuse |
KR20230162310A (ko) * | 2022-05-20 | 2023-11-28 | 주식회사 카나프테라퓨틱스 | Light 단백질 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016172606A1 (fr) * | 2015-04-23 | 2016-10-27 | Baylor College Of Medicine | Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t |
WO2017025944A2 (fr) * | 2015-08-13 | 2017-02-16 | Brigham Young University | Car macrophage (moto-car) en immunothérapie |
US20180186855A1 (en) * | 2016-03-23 | 2018-07-05 | Alector Llc | Chimeric receptors and methods of use thereof |
WO2018140831A2 (fr) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Conjugués ciblant les tumeurs et leurs méthodes d'utilisation |
US20180244748A1 (en) * | 2015-07-28 | 2018-08-30 | The Trustees Of The University Of Pennsylvania | Modified Monocytes/Macrophage Expressing Chimeric Antigen Receptors and Uses Thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108064283B (zh) * | 2015-02-24 | 2024-01-09 | 加利福尼亚大学董事会 | 结合触发的转录开关及其使用方法 |
WO2019055946A1 (fr) * | 2017-09-18 | 2019-03-21 | F1 Oncology, Inc. | Méthodes et compositions pour la modification génétique et l'expansion de lymphocytes et la régulation de l'activité de ces derniers |
AU2017244108B2 (en) * | 2016-03-29 | 2021-03-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
JP2019536471A (ja) * | 2016-09-27 | 2019-12-19 | セロ・セラピューティクス・インコーポレイテッドCERO Therapeutics, Inc. | キメラエンガルフメント受容体分子 |
WO2018073394A1 (fr) * | 2016-10-19 | 2018-04-26 | Cellectis | Récepteurs d'antigènes chimériques induisant la mort cellulaire |
CN110461868A (zh) * | 2016-11-01 | 2019-11-15 | 根马布私人有限公司 | 多肽变体及其用途 |
-
2020
- 2020-04-30 JP JP2021564784A patent/JP2022531325A/ja active Pending
- 2020-04-30 WO PCT/US2020/030837 patent/WO2020223550A1/fr unknown
- 2020-04-30 CA CA3135531A patent/CA3135531A1/fr active Pending
- 2020-04-30 GB GB2115849.8A patent/GB2600834A/en active Pending
- 2020-04-30 BR BR112021021843A patent/BR112021021843A8/pt unknown
- 2020-04-30 KR KR1020217038628A patent/KR20220045930A/ko unknown
- 2020-04-30 AU AU2020266595A patent/AU2020266595A1/en active Pending
- 2020-04-30 MX MX2021013355A patent/MX2021013355A/es unknown
- 2020-04-30 SG SG11202111985XA patent/SG11202111985XA/en unknown
- 2020-04-30 EP EP20798060.8A patent/EP3962497A4/fr active Pending
- 2020-04-30 CN CN202080048311.9A patent/CN114072157A/zh active Pending
-
2021
- 2021-10-28 IL IL287650A patent/IL287650A/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016172606A1 (fr) * | 2015-04-23 | 2016-10-27 | Baylor College Of Medicine | Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t |
US20180244748A1 (en) * | 2015-07-28 | 2018-08-30 | The Trustees Of The University Of Pennsylvania | Modified Monocytes/Macrophage Expressing Chimeric Antigen Receptors and Uses Thereof |
WO2017025944A2 (fr) * | 2015-08-13 | 2017-02-16 | Brigham Young University | Car macrophage (moto-car) en immunothérapie |
US20180186855A1 (en) * | 2016-03-23 | 2018-07-05 | Alector Llc | Chimeric receptors and methods of use thereof |
WO2018140831A2 (fr) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Conjugués ciblant les tumeurs et leurs méthodes d'utilisation |
Non-Patent Citations (2)
Title |
---|
DE KLEER ISMÃ ET AL: "Ontogeny of Myeloid Cells", FRONTIERS IN IMMUNOLOGY, vol. 5, 3 September 2014 (2014-09-03), XP093005846, DOI: 10.3389/fimmu.2014.00423 * |
See also references of WO2020223550A1 * |
Also Published As
Publication number | Publication date |
---|---|
SG11202111985XA (en) | 2021-11-29 |
EP3962497A1 (fr) | 2022-03-09 |
IL287650A (en) | 2021-12-01 |
CN114072157A (zh) | 2022-02-18 |
KR20220045930A (ko) | 2022-04-13 |
GB2600834A (en) | 2022-05-11 |
AU2020266595A1 (en) | 2021-11-25 |
CA3135531A1 (fr) | 2020-11-05 |
MX2021013355A (es) | 2022-02-21 |
JP2022531325A (ja) | 2022-07-06 |
WO2020223550A1 (fr) | 2020-11-05 |
BR112021021843A8 (pt) | 2022-06-21 |
BR112021021843A2 (pt) | 2022-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3962497A4 (fr) | Compositions de protéines de fusion chimériques modifiées et leurs procédés d'utilisation | |
EP3820496A4 (fr) | Constructions de fusion et leurs méthodes d'utilisation | |
IL288373A (en) | flt3l-fc fusion proteins and methods of use | |
EP3802812A4 (fr) | Compositions de protéines de fusion ciblant l'arn et méthodes d'utilisation | |
EP3788068A4 (fr) | Protéines de fusion de l'interleukine 15, et compositions et procédés thérapeutiques associés | |
EP3585425A4 (fr) | Procédés de fabrication et d'utilisation de protéines chimériques à base de domaine extracellulaire | |
GB202307301D0 (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
EP3820887A4 (fr) | Variant de la protéine de fusion pd1-4-1bbl et procédés d'utilisation associés | |
EP3962527A4 (fr) | Récepteurs chimériques et leurs méthodes d'utilisation | |
EP3833391A4 (fr) | PROTÉINES CHIMÈRES CIBLÉES SUR SIRP1alpha ET LEURS UTILISATIONS | |
EP3814385A4 (fr) | Protéine de fusion du variant de sirpalpha-4-1bbl et procédés d'utilisation associés | |
EP3960756A4 (fr) | Protéine de fusion de flagelline et son utilisation | |
EP3663319A4 (fr) | Procédé de préparation d'une nouvelle protéine de fusion et utilisation de protéine de fusion pour améliorer la synthèse de protéines | |
EP3980067A4 (fr) | Protéine de fusion anticorps-interleukine et procédés d'utilisation | |
EP3678701A4 (fr) | Compositions protéiques thérapeutiques et procédés de préparation et d'utilisation de celles-ci | |
EP3826641A4 (fr) | Compositions d'anticorps anti-fcrn et leurs procédés d'utilisation | |
EP3768315A4 (fr) | Compositions de variant fc et leurs procédés d'utilisation | |
EP3950720A4 (fr) | Protéine de fusion et son utilisation | |
EP4045531A4 (fr) | Procédés et compositions comprenant des échafaudages fab modifiés et des domaines de liaison fab de protéine g | |
EP3600429A4 (fr) | Protéine de fusion de l'il-37 et procédés de fabrication et d'utilisation de celle-ci | |
EP4028034A4 (fr) | Protéines réceptrices orthogonales chimériques et leurs méthodes d'utilisation | |
EP3927830A4 (fr) | Polypeptides chimères et méthodes d'utilisation de ces derniers | |
EP3882277A4 (fr) | Protéine de fusion et son utilisation | |
EP3836944A4 (fr) | Compositions à base de fermeture à glissière à leucine et méthodes d'utilisation | |
EP3816181A4 (fr) | Protéine de fusion du fviii améliorée et utilisation associée |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20211113 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40070246 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20221216 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/00 20060101ALI20221212BHEP Ipc: A61K 38/19 20060101ALI20221212BHEP Ipc: A61K 31/7088 20060101ALI20221212BHEP Ipc: A61K 9/00 20060101ALI20221212BHEP Ipc: A61P 35/00 20060101ALI20221212BHEP Ipc: A61K 38/15 20060101ALI20221212BHEP Ipc: A61K 35/15 20150101AFI20221212BHEP |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230515 |